



A leader in biopharmaceutical advancements of plant-derived cannabinoid-based products

Avicanna is a commercial stage, diversified and vertically-integrated Canadian biopharmaceutical company focused on the research, development and commercialization of plant-derived cannabinoid-based products for global consumer, medical cannabis, and pharmaceutical market segments.

Avicanna is a seasoned leader in cannabinoid research and development

Primarily conducts R&D at headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and collaborates with leading Canadian academic and medical institutions. In addition to its burgeoning pharmaceutical pipeline, Avicanna's team of experts have developed and commercialized several industry leading product lines.

Advanced commercial product lines

- Pura H&W™: an innovative, clinically tested line of CBD consumer derma-cosmetic products*
- RHO Phyto™: a disruptive line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced "Cannabis 2.0" products, containing oils, sprays, capsules, creams, and gels, all developed with scientific rigor, manufactured under GMP standards and supported by pre-clinical data.

World-Class Value Chain and Vertical Integration

Cultivation, Extraction, Purification, Production and Manufacturing



Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. These sustainable, economical, and industrial scale subsidiaries allow Avicanna to cultivate, process, and commercialize a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna's Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Santa Marta Golden Hemp made the first export of cannabis seeds in Colombia's history.

Commercial nation-wide in Canada in exclusive partnership with




Strategic Manufacturing with MediPharm Labs



RHO Phyto™: Medical cannabis - CBD and CBD/THC

- Positioned to be a leading global medical cannabis brand
- Advanced formulations with stability and preclinical data demonstrating enhanced bioavailability
- Strictly medical – access only through health care practitioners via pharmaceutical sales
- Ongoing real-world evidence trials (RWET) with leading Canadian medical institutions including University Health Network



*Expected to be marketed as Pura Earth in Canada. Pura Earth products in Colombia are being rebranded to Pura H&W

Fast Facts – September 4, 2020

| | |
|---------------------------|--|
| Ticker (Exchange) | AVCN (TSX) AVCNF (OTCQX) ONN (Frankfurt) |
| Stock Price (CAD) | \$1.30 |
| Market Cap | \$36M |
| Outstanding Shares | 28.4M |
| 52-Week Range | \$0.66 - \$4.84 |

All figures as of close of trading

Investment Highlights

- Three consecutive quarters of 100%+ increase in revenue and cost reductions
- Commercial stage and diversified revenue streams, across global markets including Canada, US, UK and LATAM
- Distribution agreement with Medical Cannabis by Shoppers, for the distribution of RHO Phyto products across Canada
- Proprietary R&D, preclinical and clinical platforms including 3 years of IP development, team of 10+ scientists and world-class clinical collaborations
- R&D headquarters at JLABS @ Toronto in MaRS Discovery District, inside the Johnson & Johnson Innovation Centre
- Proprietary cannabinoid product lines addressing consumer and retail, medical cannabis and Rx markets, including Pura H&W™ and RHO Phyto™
- Pharmaceutical pipeline of dermatology, neurology, oncology and pain management products
- World-class vertical integration, cultivation, extraction, purification, production, and manufacturing (global GMP Certifications)
- Low cost and sustainable cultivation, with 480,000 sq ft in Santa Marta, Colombia



Pura H&W™: Premium skincare products powered by purified CBD

The Pura H&W™ products are produced with Avicanna’s proprietary formulations using isolated CBD compounds. The company believes Pura H&W is the world’s first CBD retail product line with clinical evidence to support their applications.



| | | |
|--------|------------------|---|
| 4Q2019 | Colombia | 57 retailers and e-commerce |
| | USA | in partnership with Red White and Bloom |
| | Canada | in partnership with Medical Cannabis by Shoppers™ |
| 2H2020 | EU | e-commerce |
| | Brazil + Ecuador | |

Proprietary clinical development platform

With ongoing clinical trials on its medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s commitment to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception.

| All Clinical Trials | Pre-Clinical | Protocol Development | Protocol Established | Ethics Approval | Clinical Study |
|---|--------------|----------------------|----------------------|------------------|------------------|
| Cosmetic Trials | | | | | |
| Eczema-prone Skin | | | | | Completed |
| Acne-prone Skin | | | | | Completed |
| Anti-Aging | | | | | Completed |
| Oral Care Mouthwash | | | | | |
| Real-World Evidence (RHO Phyto) | | | | | |
| Opioid Sparing | | | | Pending Approval | |
| Pain related to Inflammatory Bowel Disorder | | | | | |
| Cognition & balance in Parkinson’s Disease | | | | | |
| Sleep/pain anxiety | | | | | |
| Pharmaceutical Trials | | | | | |
| Epidermolysis Bullosa* | | | | | Phase II Pending |
| Prevalence of Neuropathic Pain in Sickle Cell Disease | | | | | Completed |
| Neuropathic Pain in Sickle Cell Disease* | | | | | |
| Eczema* | | | | | |

*Phase I studies not required for this product; Pending regulatory approval.

Aureus™ Santa Marta

Trusted brand of cannabinoid formulations and active pharmaceutical ingredients (API).

Product offering include CBD, CBG, THC API in crude, distillate and purified format, in addition to custom formulations.



Avesta Genetica

Genetics and commercial seed program

Commercial seeds and genetics available for international markets with the first ever export of seeds out of Colombia in Q2 2020.



Milestones

| 4Q19 | 1H20 | 2H20 |
|--|--|---|
| <ul style="list-style-type: none"> ✓ USDA National Organic Program certification for hemp ✓ Retail and e-commerce launch of Pura Earth in Colombia ✓ First commercial exports of CBD APIs out of Colombia ✓ Phase I combined cultivation capacity of 480,000 sq. ft. at SMGH and Sativa Nativa | <ul style="list-style-type: none"> ✓ Agreement with Medical Cannabis by Shoppers, a subsidiary of Shoppers Drug Mart Inc., to distribute Avicanna’s RHO Phyto and Pura Earth products across Canada ✓ Completion of clinical studies on 3 CBD cosmetic products by CAIMED ✓ Industrial-scale production of CBG dominant cannabis seeds and export authorization ✓ Export of CBG dominant seeds into the US | <ul style="list-style-type: none"> ✓ Commercial launch of RHO Phyto and Pura Earth in Canada with Medical Cannabis by Shoppers • Retail and e-commerce launch of Pura H&W in the UK and US • Commencement of Epidermolysis Bullosa trials at the Hospital for Sick Children • First export of THC and finished RHO Phyto products out of Colombia • Commencement of opioid-sparing study with the University Health Network in Toronto • In Colombia, launch of RHO Phyto products under compound pharmacy model (magistral) & phytotherapeutic registration of specific RHO Phyto products • Launch of RHO Phyto products in the UK |

This document and the material contained herein are confidential and are not to be disclosed to the public. This is for information purposes only and may not be reproduced or distributed to any other person or published, in whole or part, for any purpose whatsoever. Certain information contained herein and certain oral statements made are forward-looking and relate to Avicanna Inc.’s (“Avicanna”) business strategy, product development, timing of product development, events and courses of action. Statements which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, outlook, milestones, expectations or intentions regarding the future including words or phrases such as “anticipate,” “objective,” “may,” “will,” “might,” “should,” “could,” “can,” “intend,” “expect,” “believe,” “estimate,” “predict,” “potential,” “plan,” “is designed to” or similar expressions suggest future outcomes or the negative thereof or similar variations. Forward-looking statements may include, among other things, statements about anticipated dates for revenue recognition; anticipated dates for product launches; our plans for future products and enhancements of existing products; designs for future product packaging; expected completion dates for clinical trials and product development; expected results of clinical trials; the granting of any certifications, licenses, or registrations; our future growth strategy; our future intellectual property, research and development, product formulations and business lines; intended quality standards of our joint venture with Sigma Analytics; each of our expected upcoming milestones; and our anticipated trends and challenges in the markets in which we operate. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which Avicanna will operate in the future, including the demand for our products, anticipated costs and ability to achieve goals, expected outcomes for clinical trials, the timely completion of research and development initiatives and the price of cannabis and cannabis related products. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect.

Recent News

- **Aug 24th** - Commercial export of CBG and CBD into the United States and Germany
- **Aug 18th** - Closing of \$2.7M non-brokered private placement
- **Aug 12th** - RHO Phyto medical product line launched nation-wide in Canada in partnership with Medical Cannabis by Shoppers
- **Aug 11th** - Avicanna and Red White & Bloom enter exclusive partnership for the distribution and commercialization of Pura H&W topical products in the United States
- **July 24th** - Award of two Canadian government NSERC grants: 1) Cannabinoid-based pharmaceutical formulations for the treatment of COVID-19 in collaboration with the University of Toronto; and, 2) Evaluation of cannabinoids for reversing cannabis-based toxicosis in collaboration with the University of Guelph
- **July 15th** - Participation in a Medical Cannabis Real-World Evidence (MC-RWE) Research Study Led by the University Health Network in Partnership with Medical Cannabis by Shoppers™ using its Rho Phyto™ Advanced Medical Cannabis Formulary of Products

Executive Management Team

Aras Azadian

CEO, Director, and Co-Founder

Setu Purohit

President, Director, and Co-Founder

Dave Sohi

Chief Financial Officer

Dr. Amza Ali

Chief Medical Officer

Lucas Nosiglia

CAO and President of LATAM

Dr. Justin Grant

EVP Scientific Affairs

Ivana Maric

EVP Marketing

Investor Contact

ir@avicanna.com

Company Contact

Avicanna, Inc.

480 University Ave, Suite 1502
Toronto, ON M5G 1V2 Canada
P: (647) 243-5283
www.Avicanna.com